PI3Kβ inhibition restores ALK inhibitor sensitivity in ALK-rearranged lung cancer
Wennerberg, K.; Verschuren, E. W.; Talwelkar, S.; Mäyränpää, M. I.; Schüler, J.; Linnavirta, N.; Hemmes, A.; Adinolfi, S.; Kankainen, M.; Sommergruber, W.; Levonen, A.-L.; Räsänen, J.; Knuuttila, A.
Show abstract
For non-small cell lung cancer (NSCLC) patients with ALK-rearranged tumors, treatment with ALK inhibitors can improve outcomes. However, clinical resistance typically develops over time, and in the majority of cases resistance mechanisms are ALK-independent. We generated tumor cell cultures from multiple regions of an ALK-rearranged clinical tumor specimen, and deployed functional drug screens to identify modulators of resistance to ALK inhibitors. This identified a role for PI3K{beta} and EGFR in regulating resistance to ALK inhibition. Furthermore, inhibition of ALK elicited activation of EGFR, and inhibition of PI3K{beta} rescued EGFR-mediated ALK inhibitor resistance. In ALK-rearranged primary cultures, cell lines and in vivo xenograft models, combined inhibition of ALK and PI3K{beta} prevented compensatory MAPK and PI3K-AKT pathway reactivation and selectively targeted the cancer cells. The combinatorial effect was seen even in the background of TP53 mutations and in epithelial-mesenchymal transformed cells. In conclusion, combinatorial ALK and PI3K{beta} inhibitor treatment carries promise as a treatment for ALK-rearranged NSCLC.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer 98%
- Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers 97%
- Combining RASG12C(ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a strategy for turning cold tumours hot 97%
Similar papers in this journal
Similar papers in this journal
- DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma 96%
- PIM Kinases Alter Mitochondrial Dynamics and Chemosensitivity in Lung Cancer 95%
- Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells 95%
Similar papers in this journal
- Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations 95%
- TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers 94%
- Predicting the Tumor Microenvironment Composition and Immunotherapy Response in Non-Small Cell Lung Cancer from Digital Histopathology Images 94%
Similar papers in this journal
- Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis 94%
- Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq-guided combination with sapanisertib 94%
- Pharmacological modulators of epithelial immunity uncovered by synthetic genetic tracing of SARS-CoV-2 infection responses 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.